Hikma to buy Boehringer's U.S. generics unit for $2.65 billion

(Reuters) – Hikma Pharmaceuticals Plc said it would buy German drugmaker Boehringer Ingelheim’s U.S. specialty generic drugs business for about $2.65 billion in cash and stock to bolster its presence in the United States.